Abstract
To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 167-176 |
| Number of pages | 10 |
| Journal | Journal of Neuroimmunology |
| Volume | 182 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - Jan 1 2007 |
Keywords
- Autoimmunity
- C1q
- Classical complement pathway
- Myasthenia gravis
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Neurology
- Clinical Neurology
Fingerprint Dive into the research topics of 'Pros and cons of treating murine myasthenia gravis with anti-C1q antibody'. Together they form a unique fingerprint.
Cite this
Tüzün, E., Li, J., Saini, S. S., Yang, H., & Christadoss, P. (2007). Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. Journal of Neuroimmunology, 182(1-2), 167-176. https://doi.org/10.1016/j.jneuroim.2006.10.014